Phase 3 CV outcomes trial with bempedoic acid meets primary endpoint
The Cholesterol Lowering via Bempedoic acid, an ACL-inhibiting Regimen (CLEAR) Outcomes trial met its primary endpoint of MACE-4. In this phase 3, event-driven, randomized, multicenter, double-bind, placebo-controlled trial the effect of the ATP citrate lyase inhibitor bempedoic acid on MACE-4 compared to placebo was investigated in patients with or at high risk for CVD with documented statin intolerance and elevated LDL-c levels. There were 14,000 patients at >1200 sites in 32 countries included in this study.
Bempedoic acid is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of patients wifh HeFH or esterablished ASCVD who require additional lowering of LDL-c.
A comprehensive data presentation will be given at a key medical conference in the first quarter of 2023.
Share this page with your colleagues and friends: